Tag: Hiv therapy

In recent clinical trials, Biktarvy has demonstrated sustained high rates of virologic suppression for up to five years, but understanding what are the long-term effects of Biktarvy is crucial for patients. While generally safe and well-tolerated, this powerful antiretroviral therapy can lead to some notable effects over extended periods that require monitoring.

First approved by the FDA on **June 20, 2003**, atazanavir (Reyataz) marked a significant advancement in HIV treatment as the first once-daily protease inhibitor for adults. The answer to the question 'when was atazanavir FDA approved?' highlights a key moment in the evolution of antiretroviral therapy and the shift towards more convenient, patient-friendly dosing regimens.